Home / Health / WHO Approves India's Groundbreaking HPV Vaccine
WHO Approves India's Groundbreaking HPV Vaccine
6 Oct
Summary
- India's first indigenous gender-neutral HPV vaccine secured WHO prequalification.
- Cervavac targets HPV types 16, 18, 6, and 11 for cancer and wart prevention.
- This milestone allows Cervavac to be procured by United Nations agencies.
The World Health Organization has granted prequalification to Cervavac, India's first internally developed gender-neutral quadrivalent Human Papillomavirus vaccine. This achievement by the Serum Institute of India (SII) is a significant regulatory milestone, marking their 32nd WHO prequalification.
The inclusion of Cervavac on the WHO's List of Prequalified Vaccines enables its procurement by United Nations agencies. Developed in collaboration with the Department of Biotechnology, BIRAC, WHO-IARC, and the Gates Foundation, the vaccine targets specific HPV types.
Cervavac is indicated for individuals aged nine to 26 years. In girls and women, it prevents cervical, vulvar, vaginal, and anal cancers caused by HPV types 16 and 18, along with genital warts from HPV types 6 and 11. For boys and men, it is indicated for the prevention of anal cancer and genital warts caused by these HPV types.
